Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
New strategies in GVHD prophylaxis
Autore:
Kiehl, MG; Shipkova, M; Basara, N; Blau, WI; Fauser, AA;
Indirizzi:
BMT Unit, Dept Hematol Oncol, D-55743 Idar Oberstein, Germany BMT Unit Idar Oberstein Germany D-55743 D-55743 Idar Oberstein, Germany Univ Gottingen, Dept Clin Chem, D-3400 Gottingen, Germany Univ Gottingen Gottingen Germany D-3400 Chem, D-3400 Gottingen, Germany
Titolo Testata:
BONE MARROW TRANSPLANTATION
, volume: 25, anno: 2000, supplemento:, 2
pagine: S16 - S19
SICI:
0268-3369(200005)25:<S16:NSIGP>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
VERSUS-HOST DISEASE; BONE-MARROW TRANSPLANTATION; STEM-CELL TRANSPLANTATION; MYCOPHENOLATE-MOFETIL; RANDOMIZED TRIAL; EUROPEAN-GROUP; GRAFT; CYCLOSPORINE; RECIPIENTS; LEUKEMIA;
Keywords:
mycophenolic acid; graft-versus-host disease; prophylaxis; hematopoietic stem cell transplantation;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Kiehl, MG BMT Unit, Dept Hematol Oncol, Dr Ottmar Kohler Str 2, D-55743 Idar Oberstein, Germany BMT Unit Dr Ottmar Kohler Str 2 Idar Oberstein Germany D-55743
Citazione:
M.G. Kiehl et al., "New strategies in GVHD prophylaxis", BONE MAR TR, 25, 2000, pp. S16-S19

Abstract

Despite immunosuppressive therapy using cyclosporine (CsA) and prednisolone and methotrexate (MTX), the incidence for aGVHD grade II to IV after transplantation from HLA matched unrelated donors (MUD) is 78%, the incidence for grade III and IV 36%, Since GVHD contributes to morbidity and mortality after MUD-BMT, a more effective prophylactic regimen is needed in order to prevent these transplant-associated complications. Recently, we described that mycophenolate mofetil (MMF, CellCept), an immunosuppressive agent successfully used for the prevention of acute rejection in renal allograft recipients, can safely and effectively be used for the treatment of aGVHD in hematopoietic stem cell transplantation. Information on the i,v, formulation of mycophenolic acid (MPA) is not yet available, Here we report on the i,v, formulation of MMF in hematopoietic stem cell recipients. MMF is effective in the prophylaxis of acute GVHD after stem cell transplantation; the optimal dosage needs further investigation. At the present time the relevance ofmeasurement of plasma MPA concentrations on MMF dosage is not yet understood and further evaluation is required.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 09:35:17